生物相似製劑

生物製劑大大的改變了人類的醫療歷史，尤其是在過去許多生命難以延續的疾病上，而這其中，百靈佳殷格翰佔有舉足輕重的角色。作為生物製劑製造的領導者，我們迄今已為全球生產了超過25種生物製劑。

奠基於生物技術的進步，生物相似製劑的開發也已實現，讓疾病的治療方案更加多元，並能幫助醫療體系持續發展。

在百靈佳殷格翰，我們致力於透過探索生物製劑的創新來促進醫療保健的質量和經濟的可持續性，從而改善患者的生活品質。我們深知這個價值超越了產品本身，所以我們主動尋求策略合作夥伴並竭誠歡迎創新合作，以提高病患、醫療提供者、投資者與生物製劑的整體發展。

Biosimilars

Biologic medicines have changed the world of healthcare by positively transforming the treatment of many life-limiting diseases. This success story is one Boehringer Ingelheim has helped to write.  As an industry leader in the production of biologics, we have to date manufactured more than 25 biologic medicines for global markets.

Based on the biotechnological advancements, the development of biosimilars, which are clinically equivalent alternatives to the approved reference biologic, has become a reality. To the healthcare community, the potential benefits are compelling, with the opportunity to expand overall treatment options while striving to make healthcare  systems more sustainable.

At Boehringer Ingelheim, we are committed to improving the lives of patients by exploring innovative ways for biosimilars to contribute to the quality and economic sustainability of healthcare. We know that value extends beyond the product itself, so we proactively seek strategic partnerships and welcome innovative collaborations to improve the overall experience that patients, providers, and payers have with biologics.